MedSource Awarded Services Contract for a Phase I Acute Myelogenous Leukemia and Acute Lymphoblastic Leukemia Clinical Trial

Houston, TX, May 17, 2009 --(PR.com)-- MedSource, a Contract Research Organization (CRO) providing Phase I-IV clinical trials support, announced today it has been awarded a service contract to manage a three-year Phase I study in subjects with relapsed/refractory Acute Myelogenous Leukemia or Acute Lymphoblastic Leukemia. The seven-site, US-based study will enroll up to 45 patients; each patient will participate in the study for up to a year. MedSource will provide study project management, clinical trial monitoring, and site management services

“We are particularly excited about working on this study as it combines two principal areas of our clinical focus – oncology and early phase development,” stated Eric Lund, President of MedSource.

“The compound is a monoclonal antibody and this study represents an extension of our work in this arena. MedSource has previously participated in 14 studies in these combined indications,” added Lund.

MedSource specializes in complex diseases and study designs and has experience in more than 400 trials in Phases I-IV. For more information, visit medsource.com.

About MedSource
MedSource is a premier Contract Research Organization (CRO) dedicated to delivering on-time, reliable clinical trial management services. MedSource has been providing quality results in Phase I-IV studies since 2001 and has extensive experience in complex clinical trials, with a particular expertise on oncology related programs. They have quickly grown into one of the premier CROs in North America and have been recognized as an Inc. 500 company. With clinical trial monitors located throughout North America and active vendor relationships globally, MedSource is able to quickly and effectively meet the clinical trial needs of their clients. More information about MedSource can be found at medsource.com or by calling (281) 286-2003.

###